Welcome to our dedicated page for PLXP news (Ticker: PLXP), a resource for investors and traders seeking the latest updates and insights on PLXP stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PLXP's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PLXP's position in the market.
PLx Pharma Inc. (NASDAQ: PLXP) announced a stalking horse asset purchase agreement with PLx Acquisition Company to acquire substantially all of its assets for $100,000 in cash, a credit bid of $3 million, and assumption of certain liabilities. This comes as the company plans to file for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware. The agreement is subject to higher offers and court approval. A breakup fee of $100,000 and reimbursement of expenses up to $400,000 are included in the deal. PLx is known for its FDA-approved VAZALORE liquid-filled aspirin capsules, aimed at improving absorption and minimizing stomach injury.
PLx Pharma Inc. (NASDAQ: PLXP) announced the imminent delisting of its common stock from the Nasdaq Stock Market, effective April 13, 2023, due to failing to maintain a minimum bid price of $1.00 for 30 consecutive business days. The Company was given until April 3, 2023, to regain compliance but did not do so, and it received notice from Nasdaq indicating it was not eligible for a further compliance period. Additionally, PLx has not filed its Form 10-K for the year ended December 31, 2022, exacerbating its non-compliance with Nasdaq's rules. PLx Pharma is focused on its PLxGuard™ technology to improve drug absorption and reduce stomach injury risks associated with certain medications.
PLx Pharma Inc. (NASDAQ: PLXP) reported third-quarter 2022 financial results, revealing total net sales of $0.4 million, down from $6.6 million year-over-year, impacted by trade allowances and sales return reserves. Operating expenses decreased by 22% year-over-year and 31% sequentially, totaling $9.8 million. A GAAP net loss of $8.5 million was noted, translating to ($0.30) per diluted share. The company retains a strong cash position of $25.8 million as of September 30, 2022. A strategic alternatives process is ongoing to ensure VAZALORE remains available for patients.
PLx Pharma Inc. (NASDAQ: PLXP) will announce its third quarter 2022 financial results on November 11, 2022, prior to U.S. market opening. The company focuses on its patented PLxGuard™ technology to improve drug absorption and reduce stomach injury risks. Lead products include VAZALORE 81 mg and 325 mg liquid-filled aspirin capsules. Following the earnings release, executives will host a conference call at 8:30 a.m. ET to discuss results and business progress. Details for participation and a subsequent audio webcast will be available on the company’s investor relations website.
PLx Pharma Inc. (NASDAQ: PLXP) announced a new advertising campaign for its VAZALORE 325 mg liquid-filled aspirin capsules featuring former baseball pitcher John Smoltz. Launched in September 2022 during Pain Awareness Month, the campaign highlights the unique pain relief benefits of VAZALORE, which is designed to prevent stomach irritation. VAZALORE is FDA-approved and available over the counter in over 30,000 stores nationwide. The company aims to raise awareness of effective pain management options through this initiative.
PLx Pharma Inc. (NASDAQ: PLXP) reported Q2 2022 net sales of $0.5 million, reflecting a significant decline due to $0.4 million in unfavorable adjustments. Operating expenses decreased by $4.9 million sequentially but totalled $14.2 million, up from $6.5 million year-over-year. The company experienced a GAAP net loss of $11.9 million, or ($0.43) per diluted share. Positive outcomes from a VAZALORE patient experience survey indicate high customer satisfaction, while efforts to streamline marketing and pursue strategic alternatives are underway to enhance shareholder value.
PLx Pharma Inc. (NASDAQ: PLXP) announced it will release its second quarter 2022 financial results on August 12, 2022, before U.S. markets open. The company focuses on its patented PLxGuard™ technology, aiming to enhance drug absorption and minimize stomach injury risks. Its lead products, VAZALORE 81 mg and 325 mg liquid-filled aspirin capsules, provide an innovative alternative to traditional aspirin. Following the financial results, executives will discuss the company's performance and prospects during a conference call at 8:30 a.m. ET.
PLx Pharma Inc. (NASDAQ: PLXP) announced that its President and CEO, Natasha Giordano, along with CFO Rita O’Connor, will present at the JMP Securities 2022 Life Sciences Conference on June 15, 2022, at 9:00 a.m. ET. This commercial-stage company focuses on its innovative drug delivery platform, PLxGuard™, which enhances drug absorption and minimizes stomach injury risks. Their leading product, VAZALORE, is an FDA-approved liquid-filled aspirin capsule available in 81 mg and 325 mg, designed for better absorption and reduced stomach irritation.
PLx Pharma Inc. (NASDAQ: PLXP) has gained attention for its lead product, VAZALORE, presented at the SCAI annual meeting. This innovative liquid-filled aspirin capsule aims to improve absorption and minimize gastrointestinal injury associated with traditional aspirin. A recent article in Healio highlights VAZALORE's potential as a solution for unmet needs in secondary cardiovascular disease prevention. The product is available in 81 mg and 325 mg doses, leveraging the clinically validated PLxGuard™ technology to enhance therapeutic benefits while reducing risks.
